In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Eton Pharmaceuticals Inc (NASDAQ: ETON) closed at $16.19 down -0.55% from its previous closing price of $16.28. In other words, the price has decreased by -$0.55 from its previous closing price. On the day, 0.29 million shares were traded. ETON stock price reached its highest trading level at $16.565 during the session, while it also had its lowest trading level at $16.09.
Ratios:
For a deeper understanding of Eton Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.25 and its Current Ratio is at 1.63. In the meantime, Its Debt-to-Equity ratio is 1.34 whereas as Long-Term Debt/Eq ratio is at 1.21.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on January 23, 2025, Reiterated its Buy rating but revised its target price to $33 from $17 previously.
On January 10, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $21.
H.C. Wainwright reiterated its Buy rating for the stock on January 06, 2025, while the target price for the stock was revised from $15 to $17.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 19 ’25 when Gruber James R. sold 39,082 shares for $16.16 per share. The transaction valued at 631,565 led to the insider holds 205,299 shares of the business.
Gruber James R. sold 2,631 shares of ETON for $42,149 on Aug 20 ’25. The Chief Financial Officer now owns 204,753 shares after completing the transaction at $16.02 per share. On Aug 18 ’25, another insider, Gruber James R., who serves as the Officer of the company, bought 41,713 shares for $16.61 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ETON now has a Market Capitalization of 434175936 and an Enterprise Value of 427931904. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.17 while its Price-to-Book (P/B) ratio in mrq is 18.77. Its current Enterprise Value per Revenue stands at 6.086 whereas that against EBITDA is 90.644.
Stock Price History:
The Beta on a monthly basis for ETON is 1.18, which has changed by 0.20325208 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, ETON has reached a high of $23.00, while it has fallen to a 52-week low of $11.09. The 50-Day Moving Average of the stock is -12.96%, while the 200-Day Moving Average is calculated to be -1.26%.
Shares Statistics:
For the past three months, ETON has traded an average of 296.31K shares per day and 293560 over the past ten days. A total of 26.82M shares are outstanding, with a floating share count of 22.86M. Insiders hold about 14.74% of the company’s shares, while institutions hold 66.05% stake in the company. Shares short for ETON as of 1763078400 were 2782591 with a Short Ratio of 9.39, compared to 1760486400 on 3020407. Therefore, it implies a Short% of Shares Outstanding of 2782591 and a Short% of Float of 10.91.
Earnings Estimates
. The current rating of Eton Pharmaceuticals Inc (ETON) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.2, with high estimates of $0.2 and low estimates of $0.2.
Analysts are recommending an EPS of between $0.39 and $0.39 for the fiscal current year, implying an average EPS of $0.39. EPS for the following year is $1.04, with 1.0 analysts recommending between $1.04 and $1.04.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $22.89M this quarter.It ranges from a high estimate of $25.56M to a low estimate of $21.21M. As of. The current estimate, Eton Pharmaceuticals Inc’s year-ago sales were $11.65MFor the next quarter, 3 analysts are estimating revenue of $25.7M. There is a high estimate of $28.4M for the next quarter, whereas the lowest estimate is $23M.
A total of 3 analysts have provided revenue estimates for ETON’s current fiscal year. The highest revenue estimate was $84.23M, while the lowest revenue estimate was $79.88M, resulting in an average revenue estimate of $81.57M. In the same quarter a year ago, actual revenue was $39.01MBased on 3 analysts’ estimates, the company’s revenue will be $111.5M in the next fiscal year. The high estimate is $125.79M and the low estimate is $102.6M.
